体外受精(IVF)の世界市場:類型別、機械別(使い捨て装置、培養培地、資本設備)、エンドユーズ別、地域別

【英語タイトル】In-Vitro Fertilization (IVF) Market Size, Share & Trends Analysis Report By Type, By Instrument (Disposable Devices, Culture Media, Capital Equipment), By End Use, By Region, And Segment Forecasts, 2019 - 2026

Grand View Researchが出版した調査資料(GV905063)・商品コード:GV905063
・発行会社(調査会社):Grand View Research
・発行日:2019年3月4日
・ページ数:100
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:Medical Devices
◆販売価格オプション(消費税別)
Single UserUSD4,950 ⇒換算¥539,550見積依頼/購入/質問フォーム
Multi UserUSD5,950 ⇒換算¥648,550見積依頼/購入/質問フォーム
Global/corporate LicenseUSD7,950 ⇒換算¥866,550見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、体外受精(IVF)の世界市場について調査・分析し、体外受精(IVF)の世界市場動向、体外受精(IVF)の世界市場規模、市場予測、セグメント別体外受精(IVF)市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

The global in-vitro fertilization market size is expected to reach USD 36.2 billion by 2026, based on a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 10.2% during the forecast period. The market is driven by the increasing incidence of infertility owing to lifestyle changes, government initiatives to provide better reimbursement policies, and the continuous efforts by the industry contributors. Expansion of fertility procedures for treating male infertility such as ICSI, is projected to positively influence the growth in near future.
Moreover, availability of genomic testing with the ability to prevent the transfer of genetic disease during IVF procedure is expected to drive the market. Increasing number of IVF treatments has encouraged more insurance providers to cover these procedures. This has ultimately led to competitive pricing and has moderated the treatment costs, driving the market with more treatment standardization and automation.

The behavioral shift in the society is the major factor contributing to the decreased Total Fertility Rate (TFR). This shift reflects on increasing number of working women, advanced maternal age, a shift from rural to urban societies, lower marriage rates, and delaying marriages. Such factors are projected to drive the in-vitro fertilization market during the forecast period.

Obesity is another factor leading to an increase in infertility. The fat deposited on women’s abdomen prevents follicular stimulation and produces male hormones. In case of males, rising fat deposits decrease testosterone levels and can result in lowered sperm production. Doctors recommend weight loss in men prior to fertility treatments along with proper maintenance of Body Mass Index (BMI). The U.S. Endocrine Society has established the use of Letrozole to increase the testosterone levels in obese patients.

The presence of favorable reimbursement framework, such as implementation of USD 50 million 5-year plans by the U.S Department of Defense for sperm/egg freezing coverage, is expected to drive the regional growth over the next six years. Increasing number of clinics undertaking newer techniques to offer better fertility success rates is also expected to boost the regional demand.

In Europe, the NHS covers three IVF cycles and provides coverage for gametes freezing. Moreover, the region is an attraction for international clients as countries, as countries such as Spain, have the highest number of egg donors. The clinics also provide sex identification and other IVF treatments, which are not offered in North America.

The Asia Pacific Initiative on Reproduction (ASPIRE) consists of a task force of clinicians and scientists involved in monitoring and managing fertility and Assisted Reproductive Technology (ART). Such initiatives promote awareness levels among consumers thereby, driving the growth of the IVF market.

Industry contributors are introducing advanced automation to shift the IVF treatment from invasive to minimally invasive or non-invasive procedure. The industry players are also working on technologies, which can enable older women to have enhanced fertility rates. In August 2015, OvaScience announced the results of its first published analysis comparing AUGMENT fertility treatment with a standard IVF. The results showed a significantly higher rate of selection and transfer of embryos as compared to the standard treatment.

Further key findings from the study suggest:

• Culture media led the overall market in terms of revenue in 2018. With the increasing government funding and industrial support for employees for egg/sperm freezing, the demand for cryopreservation and the required media for it, is expected to witness growth

• Increasing number of egg/sperm donor banks is expected to drive the demand for sperm, egg, and embryo processing media during the forecast period

• Fresh non-donor segment led the market in 2018. According to the 2003 – 2012 trends by the CDC, the number of fresh non-donors banking the eggs/embryos has drastically increased in U.S

• Europe led the in-vitro fertilization procedure and instrument market in 2018. High quality of treatment at economical prices and the adherence to medical standards have contributed to its market leadership

• North America also accounted for a significant market share in 2018. The standardization of procedures through automation, regulatory reforms, government funding for egg/sperm storage, and industry players introducing more IVF treatments are some contributing factors for the regional growth

• The demand for IVF treatment is expected to boom in APAC owing to fertility tourism and increasing penetration and awareness regarding the treatment in the developing economies

• Some key players in the In-vitro Fertilization (IVF) market include EMD Serono Inc.; Boston IVF; OvaScience; Thermo Fisher Scientific Inc.; Vitrolife AB; Irvine Scientific; CooperSurgical, Inc.; Cook Medical Inc.; Genea Biomedx; and Progyny Inc.

【レポートの目次】

Table of Content

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.2 Research Methodology
1.3 Information procurement
1.3.1 Purchased Database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources:
1.3.4 Primary Research
1.4 Information or Data Analysis
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective – 1:
1.10.2 Objective – 2:
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Market Segmentation
3.3 Penetration & Growth Prospect Mapping
3.4 Clinical Trials
3.5 User Perspective Analysis
3.5.1 Consumer Behavior Analysis
3.5.2 Market Influencer Analysis
3.6 Regulatory Framework & Reimbursement Scenario
3.6.1 North America
3.6.2 Europe
3.6.3 Asia Pacific
3.6.4 Latin America
3.6.5 Middle East & Africa
3.7 Market Dynamics
3.7.1 Market Driver Analysis
3.7.1.1 Rising reprotourism
3.7.1.2 Technological advancements in IVF
3.7.1.3 Favorable government funding
3.7.1.4 Late initiation of family
3.7.1.5 Increasing incidence rate of male and female infertility
3.7.1.6 Mergers and acquisitions (M&A)
3.7.2 Market Restraint Analysis
3.7.2.1 High cost of IVF treatment
3.7.2.2 Lack of regulatory framework and uniform regulations
3.7.3 Porter’s Five Forces Analysis
3.7.3.1 Bargaining power of buyers: Low
3.7.3.2 Bargaining power of suppliers: Moderate
3.7.3.3 Competitive rivalry: High
3.7.3.4 Threat of new entrants: Moderate
3.7.3.5 Threat of substitutes: Low
3.8 Business Environment Analysis Tools
3.8.1 Swot Analysis, By Pestel
3.8.1.1 Political & legal
3.8.1.2 Economic
3.8.1.3 Technological
3.8.2 Major Deals & Strategic Alliances Analysis
3.8.2.1 Joint ventures
3.8.2.2 Mergers & acquisitions
3.9 Number of IVF Cycles, by Region, 2018
Chapter 4 In-Vitro Fertilization (IVF) Market: Instrument Analysis
4.1 In-Vitro Fertilization (IVF) Market Share Analysis, 2018 & 2026
4.2 Segment Dashboard
4.3 Global In-Vitro Fertilization (IVF) Market, by Instrument, 2018 to 2026
4.4 Market Size & Forecasts and Trend Analysis, 2015 to 2026 for the Instrument
4.4.1 Culture Media
4.4.1.1 Culture media market, 2015 – 2026 (USD Million)
4.4.2 Disposable Devices
4.4.2.1 Disposable devices market, 2015 – 2026 (USD Million)
4.4.3 Capital Equipment
4.4.3.1 Capital equipment market, 2015 – 2026 (USD Million)
Chapter 5 In-Vitro Fertilization (IVF) Market: Type Analysis
5.1 IVF by Type Market Share Analysis, 2018 & 2026
5.2 Segment Dashboard
5.3 Global IVF Market, by Treatment Type, 2015 to 2026
5.4 Market Size & Forecasts and Trend Analysis, 2015 to 2026 for the Treatment Type
5.4.1 Fresh Nondonor
5.4.1.1 Fresh nondonor market, 2015 – 2026 (USD Million)
5.4.2 Frozen Nondonor
5.4.2.1 Frozen nondonor market, 2015 – 2026 (USD Million)
5.4.3 Fresh Donor
5.4.3.1 Fresh donor market, 2015 – 2026 (USD Million)
5.4.4 Frozen Donor
5.4.4.1 Frozen donor market, 2015 – 2026 (USD Million)
Chapter 6 In-Vitro Fertilization (IVF) Market: End-Use Analysis
6.1 In-Vitro Fertilization (IVF) End Use Market Share Analysis, 2018 & 2026
6.2 Segment Dashboard
6.3 Global In-Vitro Fertilization (IVF) Market, by End Use, 2018 to 2026
6.4 Market Size & Forecasts and Trend Analysis, 2015 to 2026 for the Following End Use
6.4.1 Fertility Clinics
6.4.1.1 Fertility clinics market, 2015 – 2026 (USD Million)
6.4.2 Hospitals And Others
6.4.2.1 Hospitals and others market, 2015 – 2026 (USD Million)
Chapter 7 Regional Outlook
7.1 Definitions & Scope
7.2 Regional Market Share Analysis, 2018 & 2026
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot (Market Size, CAGR, Top Verticals, Key Players, Top Trends)
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
7.5.1 North America
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.6 Market Size, & Forecasts and Trend Analysis, 2018 to 2026
7.6.1 North America
7.6.1.1 North America in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.1.2 U.S.
7.6.1.2.1 U.S. in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.1.3 Canada
7.6.1.3.1 Canada in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.2 Europe
7.6.2.1 Europe in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.2.2 UK
7.6.2.2.1 UK in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.2.3 Germany
7.6.2.3.1 Germany in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.2.4 France
7.6.2.4.1 France in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.2.5 Italy
7.6.2.5.1 Italy in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.2.6 Spain
7.6.2.6.1 Spain in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.2.7 Netherlands
7.6.2.7.1 Netherlands in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.2.8 Switzerland
7.6.2.8.1 Switzerland in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.2.9 Belgium
7.6.2.9.1 Belgium in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.3 ASIA PACIFIC
7.6.3.1 Asia Pacific in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.3.2 Japan
7.6.3.2.1 Japan in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.3.3 China
7.6.3.3.1 China (Mainland) in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.3.4 India
7.6.3.4.1 India in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.4 Latin America
7.6.4.1 Latin America in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.4.2 Brazil
7.6.4.2.1 Brazil in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.4.3 Mexico
7.6.4.3.1 Mexico in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.5 Middle East And Africa
7.6.5.1 MEA in-vitro fertilization market, 2015 – 2026 (USD Million)
7.6.5.2 South Africa
7.6.5.2.1 South Africa in-vitro fertilization market, 2015 – 2026 (USD Million)
Chapter 8 Competitive Analysis
8.1 Strategic Framework/ Competition Categorization (Key innovators, Market leaders, emerging players
8.2 Vendor Landscape
8.2.1 Strategy Mapping
8.2.2 Launch Of New Products:
8.2.3 Merger And Acquisition:
8.2.4 Geographical Expansion:
8.2.5 Partnerships:
8.3 Public Companies
8.3.1 Company Market Position Analysis (Revenue, Geographic Presence, Product Portfolio, Key Serviceable Industries, Key Alliances)
8.4 Private Companies
8.4.1 List Of Key Emerging Companies/Technology
8.4.2 Company Market Position Analysis (Geographic Presence, Product Portfolio, Key Alliance, Industry Experience)
8.5 Company Profiles
8.5.1 OVASCIENCE, INC.
8.5.1.1 Company overview
8.5.1.2 Financial performance
8.5.1.3 Product benchmarking
8.5.1.4 Strategic initiatives
8.5.1.5 SWOT analysis
8.5.2 VITROLIFE
8.5.2.1 Company overview
8.5.2.2 Financial performance
8.5.2.3 Product benchmarking
8.5.2.4 Strategic initiatives
8.5.2.5 SWOT analysis
8.5.3 EMD SERONO, INC.
8.5.3.1 Company overview
8.5.3.2 Financial performance
8.5.3.3 Product benchmarking
8.5.3.4 Strategic initiatives
8.5.3.5 SWOT analysis
8.5.4 IRVINE SCIENTIFIC
8.5.4.1 Company overview
8.5.4.2 Financial performance
8.5.4.3 Product benchmarking
8.5.4.4 Strategic initiatives
8.5.4.5 SWOT analysis
8.5.5 THE COOPER COMPANIES, INC.
8.5.5.1 Company overview
8.5.5.2 Product benchmarking
8.5.5.3 SWOT analysis
8.5.6 COOK MEDICAL (COOK GROUP)
8.5.6.1 Company overview
8.5.6.2 Product benchmarking
8.5.6.3 Strategic initiatives
8.5.6.4 SWOT analysis
8.5.7 THERMO FISHER SCIENTIFIC, INC.
8.5.7.1 Company overview
8.5.7.2 Financial performance
8.5.7.3 Product benchmarking
8.5.7.4 Strategic initiatives
8.5.7.5 SWOT analysis
8.5.8 GENEA BIOMEDX
8.5.8.1 Company overview
8.5.8.2 Product benchmarking
8.5.8.3 Strategic initiatives
8.5.8.4 SWOT analysis
8.5.9 PROGYNY, INC.
8.5.9.1 Company overview
8.5.9.2 Financial performance
8.5.9.3 Product benchmarking
8.5.9.4 Strategic initiatives
8.5.9.5 SWOT analysis
8.5.10 BOSTON IVF
8.5.10.1 Company overview
8.5.10.2 Financial performance
8.5.10.3 Product benchmarking
8.5.10.4 Strategic initiatives
8.5.10.5 SWOT analysis
8.5.11 ORIGIO
8.5.11.1 Company overview
8.5.11.2 Financial performance
8.5.11.3 Product benchmarking
8.5.11.4 Strategic initiatives
8.5.11.5 SWOT analysis
8.5.12 FERRING PHARMACEUTICAL
8.5.12.1 Company overview
8.5.12.2 Financial performance
8.5.12.3 Product benchmarking
8.5.12.4 Strategic initiatives
8.5.12.5 SWOT analysis
8.5.13 BAYER AG
8.5.13.1 Company overview
8.5.13.2 Financial performance
8.5.13.3 Product benchmarking
8.5.13.4 Strategic initiatives
8.5.13.5 SWOT analysis
8.5.14 MERCK & CO., INC.
8.5.14.1 Company overview
8.5.14.2 Financial performance
8.5.14.3 Product benchmarking
8.5.14.4 Strategic initiatives
8.5.14.5 SWOT analysis
8.5.15 ORGANON
8.5.15.1 Company overview
8.5.15.2 Financial performance
8.5.15.3 Product benchmarking
8.5.15.4 Strategic initiatives
8.5.15.5 SWOT analysis
Chapter 9 KOL Commentary & Recommendations

List of Tables

TABLE 1 List of secondary sources
TABLE 2 List of Abbreviation
TABLE 3 Clinical trial analysis
TABLE 4 Cost variations for IVF treatment throughout different countries
TABLE 5 Comparison between fresh and frozen donor treatment (USA)
TABLE 6 North America IVF Market, by Country, 2015 - 2026 (USD Million)
TABLE 7 North America IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 8 North America IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 9 North America IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 10 U.S. IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 11 U.S. IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 12 U.S. IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 13 Current Canadian Law on ART
TABLE 14 Canada IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 15 Canada IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 16 Canada IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 17 Europe IVF Market, by Country, 2015 - 2026 (USD Million)
TABLE 18 Europe IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 19 Europe IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 20 Europe IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 21 UK IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 22 UK IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 23 UK IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 24 Germany IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 25 Germany IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 26 Germany IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 27 France IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 28 France IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 29 France IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 30 Italy IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 31 Italy IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 32 Italy IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 33 Spain IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 34 Spain IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 35 Spain IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 36 Netherlands IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 37 Netherlands IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 38 Netherlands IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 39 Switzerland IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 40 Switzerland IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 41 Switzerland IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 42 Belgium IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 43 Belgium IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 44 Belgium IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 45 Asia Pacific IVF Market, by Country, 2015 - 2026 (USD Million)
TABLE 46 Asia Pacific IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 47 Asia Pacific IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 48 Asia Pacific IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 49 Japan IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 50 Japan IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 51 Japan IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 52 China IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 53 China IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 54 India IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 55 India IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 56 India IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 57 Latin America IVF Market, by Country, 2015 - 2026 (USD Million)
TABLE 58 Latin America IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 59 Latin America IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 60 Latin America IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 61 Brazil IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 62 Brazil IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 63 Brazil IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 64 Mexico IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 65 Mexico IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 66 Mexico IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 67 Middle East & Africa IVF Market, by Country, 2015 - 2026 (USD Million)
TABLE 68 Middle East & Africa IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 69 Middle East & Africa IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 70 Middle East & Africa IVF Market, by End Use, 2015 - 2026 (USD Million)
TABLE 71 South Africa IVF Market, by Instrument, 2015 - 2026 (USD Million)
TABLE 72 South Africa IVF Market, by Type, 2015 - 2026 (USD Million)
TABLE 73 South Africa IVF Market, by End Use, 2015 - 2026 (USD Million)

【掲載企業】

OVASCIENCE, INC., VITROLIFE, EMD SERONO, INC. , IRVINE SCIENTIFIC, THE COOPER COMPANIES, INC., COOK MEDICAL (COOK GROUP), THERMO FISHER SCIENTIFIC, INC., GENEA BIOMEDX, PROGYNY, INC., BOSTON IVF, ORIGIO, FERRING PHARMACEUTICAL, BAYER AG, MERCK & CO., INC., ORGANON

★調査レポート[体外受精(IVF)の世界市場:類型別、機械別(使い捨て装置、培養培地、資本設備)、エンドユーズ別、地域別] (コード:GV905063)販売に関する免責事項を必ずご確認ください。
★調査レポート[体外受精(IVF)の世界市場:類型別、機械別(使い捨て装置、培養培地、資本設備)、エンドユーズ別、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆